Takeda invests $760M+ into new plasma-derived therapy manufacturing site in Japan
The Japanese pharma giant Takeda will be making a significant investment close to home as it expands its capabilities in plasma therapy manufacturing.
Takeda announced on Thursday that it will be constructing a new manufacturing facility to produce plasma-derived therapies or PDTs. According to a Takeda release, it plans to invest $761.8 million into the project, marking its largest investment into an expansion of manufacturing capacity in Japan and will be the largest PDT manufacturing site in the country.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.